• Member News

Practical completion achieved for Bellhouse Building at The Oxford Science Park

The Oxford Science Park (TOSP), one of the UK's leading parks for science and technology companies, is pleased to announce that its newest facility, the 30,000 sq ft Bellhouse Building, has reached practical completion.

Consilium Strategic Communications Advises Hyloris Pharmaceuticals on its Successful Initial Public Offering

Euronext Brussels listing of innovative specialty pharmaceutical company, raises minimum of EUR 62 million

Symbiosis secures £1 million of growth finance from Allied Irish Bank (GB)

Symbiosis Pharmaceutical Services has secured £1million of finance from Allied Irish Bank (GB) to support its 2020 growth strategy.

Coulter Partners secures Supervisory Board Directors for Pharming Group

Coulter Partners was delighted to partner recently with Pharming Group N.V. (Euronext Amsterdam: PHARM), to secure the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors.

Major boost in global fight against antimicrobial resistance as AMR Centre receives share of Strength in Places Fund award

The AMR Centre has combined forces to attract much needed investment to combat the global threat of antimicrobial resistance (AMR) resulting in a successful bid for a £114 million project supported by UK Research and Innovation (UKRI).

RoslinCT announces the construction of a new Cell & Gene therapy manufacturing facility

RoslinCT - a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) - announces initiation of construction for the expansion of their new manufacturing centre.

Illumina Accelerator Welcomes First Global Cohort of Genomics Startups

Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.

UK precision medicine company PrecisionLife identifies 68 genes associated with high risk of severe COVID-19, suggesting opportunities for genomic biomarkers and new treatment options

25 June 2020, Oxfordshire, UK - Scientists from UK-headquartered AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyze the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2.

Symbiosis and AstraZeneca Sign Supply Agreement for Sterile Manufacture of COVID-19 Vaccine for Clinical Trials

Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials.

Medannex presents data on its immunomodulatory anticancer agent MDX-124 at AACR Annual Meeting

Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the American Association for Cancer Research (AACR). The data concerns the company’s proprietary immunomodulatory agent, MDX-124, which has been shown to reduce cancer cell growth by up to 76% in a broad range of cancer cell lines.